CLRB News and Press, Cellectar Biosciences Inc. From 05/13/19

Gainers:  Cellectar Biosciences (NASDAQ: CLRB ) +7% . More news on: Cellectar Biosciences, Inc., INSYS Therapeutics, Inc., Soliton, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Thinly traded nano cap Cellectar Biosciences ( CLRB +5.6% ) is up on more than a 4x surge in volume on the heels of Fast Track status in the U.S. for lead candidate CLR 131 for the fourth line (or greater) treatment of relapsed/refractory multiple myeloma. More news on: Cellectar Biosc...

Amber Road (NYSE: AMBR ) +26%  on being acquired by E2open. More news on: Amber Road, Inc., Onconova Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Stocks on the move, Read more ...

FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Admi...

Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.76  misses by $0.26 . Cash and cash equivalents of $10.48M Press Release More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131 in relapsed/refractory multiple myeloma ...

Soleno Therapeutics (NASDAQ: SLNO ) -10% . More news on: Soleno Therapeutics, Inc., Tencent Music Entertainment Group, Cellectar Biosciences, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) is up  40%  premarket on robust volume on the heels of the FDA's Import Alert exemption granted to the Centre for Probe Development and Commercialization (CPDC) related to the company's pediatric IND for lead candidate ...

Altimmune (NASDAQ: ALT ) +44%  on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...

FLORHAM PARK, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Ad...